Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
-
Trump's name added to Kennedy Center facade, a day after change
-
West Indies 206-2, trail by 369, after Duffy's double strike
-
US strikes Islamic State group in Syria after deadly attack on troops
-
Epstein files opened: famous faces, many blacked-out pages
-
Ravens face 'special' Patriots clash as playoffs come into focus
-
Newly released Epstein files: what we know
-
Musk wins US court appeal of $56 bn Tesla pay package
-
US judge voids murder conviction in Jam Master Jay killing
-
Trump doesn't rule out war with Venezuela
-
Haller, Aouar out of AFCON, Zambia coach drama
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
Bologna win shoot-out with Inter to reach Italian Super Cup final
-
Brandt and Beier send Dortmund second in Bundesliga
-
Trump administration begins release of Epstein files
-
UN Security Council votes to extend DR Congo mission by one year
-
Family of Angels pitcher, club settle case over 2019 death
-
US university killer's mystery motive sought after suicide
-
Rubio says won't force deal on Ukraine as Europeans join Miami talks
-
Burkinabe teen behind viral French 'coup' video has no regrets
-
Brazil court rejects new Bolsonaro appeal against coup conviction
-
Three-time Grand Slam winner Wawrinka to retire in 2026
-
Man Utd can fight for Premier League title in next few years: Amorim
-
Pandya blitz powers India to T20 series win over South Africa
-
Misinformation complicated Brown University shooting probe: police
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
Stocks advance as markets cheer weak inflation
-
Emery says rising expectations driving red-hot Villa
-
Three killed in Taipei metro attacks, suspect dead
-
Seven Colombian soldiers killed in guerrilla attack: army
-
Amorim takes aim at Man Utd youth stars over 'entitlement'
-
Mercosur meets in Brazil, EU eyes January 12 trade deal
-
US Fed official says no urgency to cut rates, flags distorted data
-
Rome to charge visitors for access to Trevi Fountain
-
Spurs 'not a quick fix' for under-fire Frank
-
Poland president accuses Ukraine of not appreciating war support
-
Stocks advance with focus on central banks, tech
-
Amorim unfazed by 'Free Mainoo' T-shirt ahead of Villa clash
-
PSG penalty hero Safonov ended Intercontinental win with broken hand
-
French court rejects Shein suspension
-
'It's so much fun,' says Vonn as she milks her comeback
-
Moscow intent on pressing on in Ukraine: Putin
-
UN declares famine over in Gaza, says 'situation remains critical'
-
Guardiola 'excited' by Man City future, not pondering exit
-
Czechs name veteran coach Koubek for World Cup play-offs
-
PSG penalty hero Safonov out until next year with broken hand
-
Putin says ball in court of Russia's opponents in Ukraine talks
-
Czech Zabystran upsets Odermatt to claim Val Gardena super-G
-
NGOs fear 'catastrophic impact' of new Israel registration rules
-
US suspends green card lottery after MIT professor, Brown University killings
-
Arsenal in the 'right place' as Arteta marks six years at club
NYSE - LSE
Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.
Olayinka Oyebola & Co. has worked diligently to complete the audits in accordance with Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy and integrity of Bionoid's financial reporting. The firm remains on track to finalize the company's 2024 financial statements as scheduled, further strengthening Bionoid's financial standing.
"The completion of our 2022 and 2023 audits is a critical achievement for Bionoid and underscores our dedication to financial accountability," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "As we continue our expansion through strategic acquisitions and AI-driven growth initiatives, maintaining strong financial governance remains a top priority. We appreciate the expertise and professionalism of Olayinka Oyebola & Co. and look forward to the timely completion of our 2024 financials."
Bionoid remains focused on scaling its operations through revenue-generating e-commerce acquisitions and the integration of its AI Maverick platform, positioning the company for sustainable growth and enhanced investor confidence.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform enhances customer engagement and operational efficiency, supporting the company's mission to deliver innovative, AI-driven solutions for long-term growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
O.M.Souza--AMWN
